 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, M.D., the Companys Executive Vice President of Research and Development and Chief Medical Officer, will serve as a panel member at the invitation of the Food and Drug Administration FDA and provide industry perspective at the FDAs public workshop entitled Advancing Animal Models for Antibacterial Drug Development. The public workshop will be held on March 5th 2020 at the FDAs White Oak campus in Silver Spring, MD. 